r the first nine months of 2025, up 40.4% year-on-year at constant currency. Growth was driven by Nemluvio’s continued outperformance, which more than offset the anticipated decline in the mature portfolio, particularly in the U.S.

Nemluvio’s net sales for the first nine months were 263 million USD, predominantly from the U.S. and prurigo nodularis, although atopic dermatitis started contributing to a greater share of sales in the third quarter. Nemluvio’s uptake in International markets continues with strong performance in Germany and additional launches in Austria, Switzerland, the United Kingdom, and Denmark.

Galderma continues to invest in its Therapeutic Dermatology portfolio, especially Nemluvio, and also in its mature brands capitalizing on a leading position in acne in International markets. International expansion efforts for Nemluvio continued during the third quarter with new regulatory submissions, building on the momentum of the novel
=*=*=*=*=*=
当前为第9/31页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页